Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma.

[1]  D. Hayes,et al.  Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Sepulveda,et al.  Evaluation of EGFR mutation status in cytology specimens: An institutional experience , 2013, Diagnostic cytopathology.

[3]  L. Sakr,et al.  Cytology-based treatment decision in primary lung cancer: is it accurate enough? , 2012, Lung cancer.

[4]  M. Tsao,et al.  A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[6]  S. Dacic,et al.  Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. , 2011, American journal of clinical pathology.

[7]  C. Sima,et al.  Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens , 2011, Modern Pathology.

[8]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[9]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[11]  Anna Spreafico,et al.  The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  L. Einhorn.  First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yukiko Nakamura,et al.  Influence of histological type, smoking history and chemotherapy on survival after first‐line therapy in patients with advanced non‐small cell lung cancer , 2007, Cancer science.

[15]  M Volante,et al.  ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[17]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[19]  M. Fukushima,et al.  Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). , 2004, Lung cancer.

[20]  M. Thun,et al.  Cigarette smoking and changes in the histopathology of lung cancer. , 1997, Journal of the National Cancer Institute.

[21]  J. E. Stark,et al.  Diagnostic accuracy of cytology and biopsy in primary bronchial carcinoma. , 1979, Thorax.

[22]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[23]  M. L. R. D. Christenson,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2012 .

[24]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[25]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[26]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .